Page last updated: 2024-10-27

foscarnet and Hepatorenal Syndrome

foscarnet has been researched along with Hepatorenal Syndrome in 1 studies

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.

Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leung, PYM1
Tran, T1
Testro, A1
Paizis, K1
Kwong, J1
Whitlam, JB1

Other Studies

1 other study available for foscarnet and Hepatorenal Syndrome

ArticleYear
Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:6

    Topics: Aged; Antiviral Agents; Cytomegalovirus; Drug Resistance, Viral; Foscarnet; Hepatorenal Syndrome; Hu

2019